2022
Sustained virological response after treatment with direct antiviral agents in individuals with HIV and hepatitis C co‐infection
Lodi S, Klein M, Rauch A, Epstein R, Wittkop L, Logan R, Rentsch C, Justice A, Touloumi G, Berenguer J, Jarrin I, Egger M, Puoti M, Monforte A, Gill J, Ceron D, van Sighem A, Linas B, van der Valk M, Hernán M, Collaboration H. Sustained virological response after treatment with direct antiviral agents in individuals with HIV and hepatitis C co‐infection. Journal Of The International AIDS Society 2022, 25: e26048. PMID: 36562643, PMCID: PMC9784654, DOI: 10.1002/jia2.26048.Peer-Reviewed Original ResearchConceptsSustained virological responseHCV RNA testingDAA treatmentSVR ratesVirological responseProbability of SVRHepatitis C virus (HCV) cureRoutine HCV RNA testingActing antiviral (DAA) treatmentDAA treatment initiationCD4 cell countDirect antiviral agentsPresence of cirrhosisHCV RNA testEnd of treatmentClinical strataDAA recipientsHIV-HCVSVR assessmentSVR statusHIV acquisitionClinical characteristicsAntiviral treatmentTreatment initiationHCV genotypes
2011
The Risk of Incident Coronary Heart Disease Among Veterans With and Without HIV and Hepatitis C
Freiberg MS, Chang CC, Skanderson M, McGinnis K, Kuller LH, Kraemer KL, Rimland D, Goetz MB, Butt AA, Barradas M, Gibert C, Leaf D, Brown ST, Samet J, Kazis L, Bryant K, Justice AC. The Risk of Incident Coronary Heart Disease Among Veterans With and Without HIV and Hepatitis C. Circulation Cardiovascular Quality And Outcomes 2011, 4: 425-432. PMID: 21712519, PMCID: PMC3159506, DOI: 10.1161/circoutcomes.110.957415.Peer-Reviewed Original ResearchConceptsHuman immunodeficiency virusHepatitis C virusHIV-HCVCensoring eventVeterans Aging Cohort Study Virtual CohortIncident coronary heart diseaseCoronary heart disease riskHeart disease riskCoronary heart diseaseHIV-1 RNARisk of CHDIncidence of CHDHCV statusVeteran EnrolleesAdjusted riskAntiretroviral therapyCD4 countCHD eventsHCV infectionHepatitis CCHD riskImmunodeficiency virusC virusHeart diseaseRisk factors
2009
The Association Between the Receipt of Lipid Lowering Therapy and HIV Status Among Veterans Who Met NCEP/ATP III Criteria for the Receipt of Lipid Lowering Medication
Freiberg MS, Leaf DA, Goulet JL, Goetz MB, Oursler KK, Gibert CL, Rodriguez-Barradas MC, Butt AA, Justice AC. The Association Between the Receipt of Lipid Lowering Therapy and HIV Status Among Veterans Who Met NCEP/ATP III Criteria for the Receipt of Lipid Lowering Medication. Journal Of General Internal Medicine 2009, 24: 334-340. PMID: 19127386, PMCID: PMC2642578, DOI: 10.1007/s11606-008-0891-7.Peer-Reviewed Original ResearchConceptsNCEP/ATP III criteriaATP III criteriaHIV viral loadViral loadAdult Treatment Panel guidelinesHigher HIV viral loadFive-site studyLipid lowering medicationsVeterans Aging CohortHIV infection statusLipid-Lowering TherapyProspective observational cohortCross-sectional analysisHIV-HCVLowering therapiesModifiable mediatorsObservational cohortResultsThe prevalenceHIV infectionHIV statusPharmacy dataCardiovascular diseasePanel guidelinesMAIN OUTCOMELow prevalence